Erlotinib
Clinical data | |
---|---|
Trade names | Tarceva |
Other names | Erlotinib hydrochloride |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605008 |
License data | |
Pregnancy category | |
By mouth | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 59% |
Protein binding | 95% |
Metabolism | Liver (mainly CYP3A4, less CYP1A2) |
Elimination half-life | 36.2 hrs (median) |
Excretion | >98% as metabolites, of which >90% via feces, 9% via urine |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Erlotinib, sold under the brand name Tarceva among others, is a
Common side effects include rash, diarrhea, muscle pain, joint pain, and cough.
Erlotinib was approved for medical use in the United States in 2004.
Medical uses
Lung cancer
Erlotinib in unresectable non-small cell lung cancer when added to chemotherapy improves
In lung cancer, erlotinib has been shown to be effective in patients with or without EGFR mutations, but appears to be more effective in patients with EGFR mutations.[11][12] Overall survival, progression-free survival and one-year survival are similar to standard second-line therapy (docetaxel or pemetrexed). Overall response rate is about 50% better than standard second-line chemotherapy.[12] Patients who are non-smokers, and light former smokers, with adenocarcinoma or subtypes like BAC are more likely to have EGFR mutations, but mutations can occur in all types of patients. A test for the EGFR mutation has been developed by Genzyme.[13]
Pancreatic cancer
In November 2005, the FDA approved erlotinib in combination with gemcitabine for treatment of locally advanced, unresectable, or metastatic pancreatic cancer.[14]
Resistance to treatment
As with other ATP competitive small molecule tyrosine kinase inhibitors, such as imatinib in CML, patients rapidly develop resistance. In the case of erlotinib this typically occurs 8–12 months from the start of treatment. Over 50% of resistance is caused by a mutation in the ATP binding pocket of the EGFR kinase domain involving substitution of a small polar threonine residue with a large nonpolar methionine residue (T790M).[15]
Approximately 20% of drug resistance is caused by amplification of the
Side effects
Common
- Rash occurs in the majority of patients. This resembles acne and primarily involves the face and neck. It is self-limited and resolves in the majority of cases, even with continued use. Some clinical studies have indicated a correlation between the severity of the skin reactions and increased survival though this has not been quantitatively assessed.[18] The Journal of Clinical Oncology reported in 2004 that "cutaneous [skin] rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies."[19] The newsletter Lung Cancer Frontiers reported in its October 2003 issue, "Patients with moderate to severe cutaneous reactions [rashes] have a far better survival, than those with only mild reactions and much better than those with no cutaneous manifestations of drug effects."[20]
- Diarrhea
- Loss of appetite
- Fatigue[9]
- Partial hair loss (by strands, not typically in clumps)
Rare
- interstitial dyspnea. This may be severe and must be considered among those patients whose breathing acutely worsens.
- ingrown hairs, such as eyelashes
- gastrointestinal tract toxicity
- serious or fatal gastrointestinal tract perforations
- serious or fatal
- skin toxicity
- bullous, blistering, and exfoliative skin conditions (some fatal)
- Stevens–Johnson syndrome/toxic epidermal necrolysis[21]
- ocular disorders
- corneal lesions
- Pulmonary toxicity
- interstitial pneumonitis
- bronchiolitis obliterans with organizing pneumonia(BOOP)
- pulmonary fibrosis
- fatal asymmetric interstitial lung disease[22]
Interactions
Erlotinib is not a substrate for either of hepatic
Erlotinib is mainly metabolized by the liver enzyme CYP3A4. Compounds which induce this enzyme (i.e. stimulate its production), such as St John's wort, can lower erlotinib concentrations, while inhibitors can increase concentrations.[25]
Mechanism
Erlotinib is an epidermal growth factor receptor inhibitor (
Society and culture
It is marketed in the United States by
The drug's U.S. patent expired in 2020.[29] In May 2012, the US District Court of Delaware passed an order in favor of OSI Pharmaceutical LLC against Mylan Pharmaceuticals upholding the validity of the patent for Erlotinib.[citation needed] In India, generic pharmaceutical firm Cipla is battling[when?] with Roche against the Indian patent for this drug.[30][31]
References
- ^ "Erlotinib (Tarceva) Use During Pregnancy". Drugs.com. 1 November 2019. Archived from the original on 12 November 2019. Retrieved 23 December 2019.
- ^ a b "Tarceva (Erlotinib hydrochloride)". Roche Products Pty Limited. Australian Product Information. 31 August 2022.
- ^ a b c d "Tarceva- erlotinib hydrochloride tablet". DailyMed. 12 December 2018. Archived from the original on 6 August 2020. Retrieved 23 December 2019.
- ^ a b c d e f g h "Erlotinib Monograph for Professionals". Drugs.com. Archived from the original on 24 December 2019. Retrieved 12 November 2019.
- ^ "Drug Approval Package: Tarceva (Erlotinib) NDA #021743". U.S. Food and Drug Administration (FDA). 28 March 2005. Archived from the original on 23 December 2019. Retrieved 23 December 2019.
- hdl:10665/325771.
- ^ "2009 - SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC". Archived from the original on 22 December 2010. Retrieved 18 December 2010.
- ^ "April 2010 - Tarceva Indication Announcement Letter" (PDF). Archived (PDF) from the original on 16 July 2011. Retrieved 18 December 2010.
- ^ PMID 36267895.
- S2CID 10218263.
- PMID 23361373.
- ^ PMID 23244131.
- ^ "Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test". Roche (Press release). Archived from the original on 24 February 2022. Retrieved 10 January 2020.
- ^ Takimoto CH, Calvo E (15 April 2009), Principles of Oncologic Pharmacotherapy, archived from the original on 15 May 2009, retrieved 18 June 2009
- PMID 17085664.
- S2CID 23254145.
- PMID 18093943.
- PMID 16290256.
- PMID 15310767.
- ^ Petty TL (2003). "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer". Journal of Clinical Oncology. 1 (17): 3–4.
- PMID 20382753.
- PMID 22889962.
- PMID 24643910.
- PMID 24807167.
- ^ Haberfeld, H, ed. (2010). Austria-Codex (in German) (2010/2011 ed.). Vienna: Österreichischer Apothekerverlag.
- S2CID 10555942.
- PMID 12848590.
- ^ "FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients". GenomeWeb. 15 May 2013. Archived from the original on 6 September 2019. Retrieved 10 January 2020.
- ^ "Erlotinib - Generic Drug Details". DrugPatentWatch.com. Archived from the original on 28 April 2016.
- ^ "Roche and India's Glenmark reach truce over generic Tarceva". GaBI Online. 22 January 2016. Archived from the original on 24 December 2019. Retrieved 23 December 2019.
- ^ "Cancer drug: Supreme Court allows Cipla to withdraw appeal against Roche". The Economic Times. 16 June 2017. Archived from the original on 24 December 2019. Retrieved 23 December 2019.
External links
- "Erlotinib". National Cancer Institute.